Q3 EPS Estimate for Mind Medicine (MindMed) Cut by Analyst

Key Points

• Roth Capital has lowered its Q3 2025 earnings per share (EPS) estimate for Mind Medicine (MindMed) to ($0.49), down from a previous estimate of ($0.39).
• The company's recent earnings report showed a loss of ($0.50) per share, missing analysts' expectations by ($0.12).
• Despite the earnings revision, Mind Medicine holds a consensus rating of "Buy" with an average price target of $24.71 from multiple analysts.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Equities research analysts at Roth Capital reduced their Q3 2025 earnings per share (EPS) estimates for Mind Medicine (MindMed) in a report issued on Monday, August 4th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings per share of ($0.49) for the quarter, down from their previous forecast of ($0.39). The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share. Roth Capital also issued estimates for Mind Medicine (MindMed)'s Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($2.13) EPS, FY2027 earnings at $0.84 EPS, FY2028 earnings at $4.21 EPS and FY2029 earnings at $7.77 EPS.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.12).

Several other equities research analysts have also recently commented on the company. Chardan Capital reaffirmed a "buy" rating and set a $20.00 price objective on shares of Mind Medicine (MindMed) in a research report on Friday, August 1st. Oppenheimer began coverage on Mind Medicine (MindMed) in a research note on Monday, August 4th. They set an "outperform" rating and a $25.00 price target for the company. Finally, Cantor Fitzgerald raised Mind Medicine (MindMed) to a "strong-buy" rating in a research report on Tuesday, May 13th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $24.71.

Mind Medicine (MindMed) Stock Down 1.4%

Shares of NASDAQ:MNMD traded down $0.14 on Wednesday, hitting $9.85. 1,184,575 shares of the company traded hands, compared to its average volume of 1,271,573. Mind Medicine has a 52 week low of $4.70 and a 52 week high of $10.44. The company has a quick ratio of 4.98, a current ratio of 4.98 and a debt-to-equity ratio of 0.22. The stock has a 50 day simple moving average of $8.08 and a 200-day simple moving average of $7.21. The company has a market cap of $744.17 million, a PE ratio of -6.44 and a beta of 2.49.

Insider Buying and Selling

In other news, insider Mark Sullivan sold 11,491 shares of the company's stock in a transaction that occurred on Wednesday, June 25th. The stock was sold at an average price of $6.80, for a total transaction of $78,138.80. Following the sale, the insider directly owned 305,130 shares of the company's stock, valued at $2,074,884. This represents a 3.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Daniel Karlin sold 7,848 shares of the stock in a transaction on Wednesday, June 25th. The shares were sold at an average price of $6.80, for a total value of $53,366.40. Following the sale, the insider owned 438,329 shares in the company, valued at $2,980,637.20. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 45,830 shares of company stock valued at $311,644. Corporate insiders own 2.45% of the company's stock.

Institutional Trading of Mind Medicine (MindMed)

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC grew its position in shares of Mind Medicine (MindMed) by 67.4% during the 2nd quarter. CWM LLC now owns 4,459 shares of the company's stock worth $29,000 after buying an additional 1,796 shares in the last quarter. Diadema Partners LP bought a new stake in Mind Medicine (MindMed) during the fourth quarter valued at about $33,000. Virtus ETF Advisers LLC bought a new stake in Mind Medicine (MindMed) during the fourth quarter valued at about $70,000. Sharpepoint LLC bought a new stake in Mind Medicine (MindMed) during the fourth quarter valued at about $71,000. Finally, KLP Kapitalforvaltning AS bought a new stake in Mind Medicine (MindMed) during the fourth quarter valued at about $72,000. Hedge funds and other institutional investors own 27.91% of the company's stock.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.